Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method of treating or preventing a disease or condition in which the inhibition of kinase Itk activity is beneficial comprising administering ~~The use~~ of a compound of formula (I)



(I)

wherein:

R^3 represents halogen, CN, C1 to 3 alkyl or C1 to 3 alkoxy;

Ar represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S;

R^1 represents H, halogen, CN, C1 to 6 alkyl, NO_2, SO_2Me, C1 to 6 alkynyl, CH_2OH, OR^2, $(CH_2)_nNR^4R^5$ or phenyl optionally substituted by NH_2;

m represents an integer 1 or 2; and when m represents 2, each R^1 may be selected independently;

n represents an integer 0 or 1;

R^2 represents H or C1 to 4 alkyl; said C1 to 4 alkyl being optionally further substituted by a group selected from Ar^1, $CONH_2$, CO_2Et, OH, NR^6R^7, halogen and epoxy; and when substituted by NR^6R^7 or halogen, said alkyl is optionally further substituted by OH;

R^4 represents H, C1 to 4 alkyl or CH_2Ar^2;

R^5 represents H, C1 to 6 alkyl, C2 to 6 alkanoyl, SO_2-Ar^5 or CH_2Ar^2; said alkyl group being optionally further substituted by a 5 to 7 membered saturated azacyclic ring optionally incorporating one additional heteroatom selected from O, S and NR^8;

or the group $-NR^4R^5$ together represents a 5 to 7 membered saturated azacyclic ring optionally incorporating one additional heteroatom selected from O, S and NR^8;

R^6 represents H, C1 to 4 alkyl or $CH_2CH_2OCH_3$;

R^7 represents H, C1 to 6 alkyl, C3 to 6 cycloalkyl, Ar^3, a 5 or 6 membered saturated or partially unsaturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally substituted by Me, Et or CO_2Et; said C1 to 6 alkyl being optionally substituted by one or more groups selected independently from OH, CN, $CONMe_2$, CONHMe,

C1 to 4 alkoxy, halogen, NMe_2, Ar^4, and a 5 or 6 membered saturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally also incorporating a carbonyl group; said C3 to 6 cycloalkyl being optionally substituted by OH or CN;

or the group $-NR^6R^7$ together represents a 5 to 7 membered saturated azacyclic ring optionally incorporating 1 additional heteroatom selected from O and NR^9; and optionally substituted by one or more substituents selected independently from OH, NMe_2, $CONH_2$, CH_2OH, CH_2CH_2OH, phenyl, pyridyl, piperidinyl or methoxyphenyl;

R^8 represents H, C1 to 6 alkyl or CH_2Ph;

R^9 represents CH_2CH_2OH, $COCH_3$, Me, CO_2Et, CH_2CH_2OMe or a six membered aromatic or azaaromatic ring optionally further substituted by one or more substituents selected independently from Cl, CN, OMe and CF_3;

R^{10} represents H, halogen, CN, C1 to 4 alkyl, C1 to 4 alkoxy, $NR^{14}R^{15}$ or a group –X–Y–Z;

R^{14} and R^{15} independently represent H or C1 to 4 alkyl; said alkyl being optionally further substituted by OH;

X represents O, S, a bond or NR^{16} wherein R^{16} represents H or C1 to 4 alkyl; said alkyl being optionally further substituted by OH;

Y represents C1 to 4 alkyl or a bond;

Z represents:

i) phenyl, naphthyl or a 5- or 6-membered heteroaromatic ring system containing one to three heteroatoms independently selected from O, N and S; or

ii) a five- or six-membered saturated heterocyclic ring containing one or two heteroatoms independently selected from O, N and S; said ring optionally being benzo fused; or

iii) C3 to 6 cycloalkyl;

said ring Z being optionally substituted by one or more substituents independently selected from halogen, OH, C1 to 4 alkyl, C1 to 4 alkoxy, hydroxymethyl, methylsulphonyl and $NR^{17}R^{18}$;

R^{17} and R^{18} independently represent H, C1 to 4 alkyl, formyl or C2 to alkanoyl; or the group $NR^{17}R^{18}$ together represents a saturated 5 to 7 membered azacyclic ring optionally containing one further heteroatom selected from O, N and S;

Ar^1 represents phenyl, thiazolyl or thiadiazolyl, optionally further substituted by halogen;

Ar^2 represents phenyl, a 5- or 6-membered heteroaromatic ring or a benzimidazole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl or heteroaromatic or benzimidazole ring being optionally further substituted by one or two groups independently selected from halogen, C1 to 4 alkyl, CN, CH_2OH, C1 to 4 alkoxy, CO_2Me, CH_2OAc and pyridyl;

Ar^3 represents thiazolyl, triazolyl or tetrazolyl;

Ar^4 represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl, heteroaromatic or indole ring being optionally further substituted by one or two groups independently selected from halogen and OMe;

Ar^5 represents phenyl, a 5- or 6-membered heteroaromatic ring or a quinoline ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl or heteroaromatic or quinoline ring being optionally further substituted by halogen, C1 to 4 alkyl, CN, C1 to 4 alkoxy, and OCH_2CH_2CN;

or a pharmaceutically acceptable salt thereof~~, in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of kinase Itk activity is beneficial~~.

2. (Currently amended) The ~~use~~ method according to Claim 1 ~~of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of~~, wherein the disease or condition is a Th2-driven and/or mast cell-driven and/or basophil driven disease or condition~~diseases or conditions~~.

3. (Currently amended) The ~~use~~ method according to Claim 2 wherein the disease is asthma.

4. (Currently amended) The ~~use~~ method according to Claim 2 wherein the disease is allergic rhinitis.

5. (Currently amended) The ~~use~~ method according to ~~any one of Claims 1 to 4~~ Claim 1 wherein R^3 in formula (I) represents halogen.

6. (Currently amended) The ~~use~~ method according to ~~any one of Claims 1 to 4~~ Claim 1 wherein Ar in formula (I) represents phenyl.

7. (Currently amended) The ~~use~~ method according to ~~any one of Claims 1 to 6~~ Claim 1 wherein R^1 in formula (I) represents OR^2 or $(CH_2)_nNR^4R^5$.

8. (Currently amended) The ~~use~~ method according to ~~any one of Claims 1 to 6~~ Claim 1 wherein R^{10} represents halogen, CN, C1 to 4 alkyl, C1 to 4 alkoxy, $NR^{14}R^{15}$ or a group –X–Y–Z.

9. (Original) A compound of formula (Ia)



(Ia)

wherein:

R^3 represents halogen, C1 to 3 alkyl or C1 to 3 alkoxy;

R^{10} represents H;

Ar represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S;

m represents an integer 1 or 2;

when m represents 1, R^1 represents $(CH_2)_nNR^4R^5$ and n represents an integer 0 or 1;

when m represents 2, one R^1 represents chloro or OMe and the other R^1 represents $(CH_2)_nNR^4R^5$ and n represents an integer 0 or 1;

R^4 represents H or C1 to 4 alkyl;

R^5 represents CH_2Ar^2;

Ar^2 represents phenyl, a 5- or 6-membered heteroaromatic ring or a benzimidazole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl, heteroaromatic or benzimidazole ring being optionally further substituted by one or two groups independently selected from halogen, C1 to 4 alkyl, CN, CH_2OH, C1 to 4 alkoxy, CO_2Me, CH_2OAc and pyridyl;

or a pharmaceutically acceptable salt thereof.

10. (Original) A compound according to Claim 9 that is:

4-({[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]amino}methyl)benzonitrile

N-benzyl-N-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]amine

N-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]-N-(1H-imidazol-2-ylmethyl)amine

N-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]-N-(1H-imidazol-5-ylmethyl)amine

3-({[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]amino}methyl)benzonitrile

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(4-methoxybenzyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(2-methoxybenzyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(3-methoxybenzyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(2-chlorobenzyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(4-chlorobenzyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(1*H*-pyrazol-3-ylmethyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(3-chlorobenzyl)amine

[5-({[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]amino}methyl)-2-furyl]methanol

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(thien-2-ylmethyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(2-furylmethyl)amine
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(thien-3-ylmethyl)amine
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(4-methyl-1*H*-imidazol-5-yl)methyl]amine
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(3-furylmethyl)amine
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(1,3-thiazol-2-ylmethyl)amine
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(4-bromothien-2-yl)methyl]amine
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(1*H*-imidazol-4-ylmethyl)amine
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(2-methyl-1*H*-imidazol-5-yl)methyl]amine
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(3,5-dimethylisoxazol-4-yl)methyl]amine
[5-({[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]amino}methyl)-2-furyl]methyl acetate
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(5-pyridin-2-ylthien-2-yl)methyl]amine
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(1-methyl-1*H*-benzimidazol-2-yl)methyl]amine
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(2-ethyl-1*H*-imidazol-5-yl)methyl]amine
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(1-methyl-1*H*-imidazol-5-yl)methyl]amine
methyl 4-({[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]amino}methyl)-1-methyl-1*H*-pyrrole-2-carboxylate
N-benzyl-5-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)pyridin-2-amine
5-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-*N*-(3-methoxybenzyl)pyridin-2-amine
or a pharmaceutically acceptable salt thereof.

11. (Original) A compound of formula (Ib)



(Ib)

wherein:

R^3 represents halogen, C1 to 3 alkyl or C1 to 3 alkoxy;

R^{10} represents H;

Ar represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S;

m represents an integer 1 or 2;

when m represents 1, R^1 represents OR^2;

when m represents 2, one R^1 represents chloro or OMe and the other R^1 represents OR^2;

R^2 represents C3 to 4 alkyl substituted by NR^6R^7 and by OH;

R^6 represents H, C1 to 4 alkyl or $CH_2CH_2OCH_3$;

R^7 represents H, C1 to 6 alkyl, C3 to 6 cycloalkyl, Ar^3, a 5 or 6 membered saturated or partially unsaturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally substituted by Me, Et or CO_2Et; said C1 to 6 alkyl being optionally substituted by one or more groups selected independently from OH, CN, $CONMe_2$, CONHMe, C1 to 4 alkoxy, halogen, NMe_2, Ar^4, and a 5 or 6 membered saturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally also incorporating a carbonyl group; said C3 to 6 cycloalkyl being optionally substituted by OH or CN;

or the group $-NR^6R^7$ together represents a 5 to 7 membered saturated azacyclic ring optionally incorporating 1 additional heteroatom selected from O and NR^9; and optionally substituted by one or more substituents selected independently from OH, NMe_2, $CONH_2$, CH_2OH, CH_2CH_2OH, phenyl, pyridyl, piperidinyl and methoxyphenyl;

R^9 represents CH_2CH_2OH, $COCH_3$, Me, CO_2Et, CH_2CH_2OMe or a six membered aromatic or azaaromatic ring optionally further substituted by one or more substituents selected independently from Cl, CN, OMe and CF_3;

Ar^3 represents thiazolyl, triazolyl or tetrazolyl;

Ar^4 represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl, heteroaromatic or indole ring being optionally further substituted by one or two groups independently selected from halogen and OMe;
or a pharmaceutically acceptable salt thereof.

12. (Original) A compound according to Claim 11 that is:
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-pyrrolidin-1-ylpropan-2-ol
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-morpholin-4-ylpropan-2-ol
1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}pyrrolidin-3-ol
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-piperidin-1-ylpropan-2-ol
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(diethylamino)propan-2-ol
1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperidin-4-ol
1-(4-acetylpiperazin-1-yl)-3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]propan-2-ol
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[3-(dimethylamino)pyrrolidin-1-yl]propan-2-ol
4-[({2-hydroxy-3-[4-(6-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]propyl}amino)methyl]phenol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(2-hydroxyethyl)(methyl)amino]propan-2-ol

3-[{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}(methyl)amino]propanenitrile

4-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperazin-1-ol

N^2-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}-N^1,N^1,N^2-trimethylglycinamide

1-[benzyl(methyl)amino]-3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[methyl(2-phenylethyl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(4-phenylpiperazin-1-yl)propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(4-pyridin-2-ylpiperazin-1-yl)propan-2-ol

1-[2-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}amino)ethyl]imidazolidin-2-one

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(3-methoxybenzyl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(2-chlorobenzyl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(4-chlorobenzyl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(3-chlorobenzyl)amino]propan-2-ol

ethyl 4-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}amino)piperidine-1-carboxylate

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[4-(2-methoxyethyl)piperazin-1-yl]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(cyclopropylamino)propan-2-ol

3-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}amino)propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(2-methoxyethyl)amino]propan-2-ol

2-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}amino)propan-1-ol

1-(benzylamino)-3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(pyridin-3-ylmethyl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(pyridin-4-ylmethyl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(1-ethylpiperidin-3-yl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(2-morpholin-4-ylethyl)amino]propan-2-ol

1-[3-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}amino)propyl]pyrrolidin-2-one

1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperidin-3-ol

1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}prolinamide

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[4-(hydroxymethyl)piperidin-1-yl]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[2-(hydroxymethyl)piperidin-1-yl]propan-2-ol

1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperidine-4-carboxamide

1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperidine-3-carboxamide

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[4-(2-hydroxyethyl)piperazin-1-yl]propan-2-ol

2-(4-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperazin-1-yl)benzonitrile

6-(4-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperazin-1-yl)nicotinonitrile

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(1,3-thiazol-2-ylamino)propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(4-pyrazin-2-ylpiperazin-1-yl)propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(2-methoxybenzyl)amino]propan-2-ol

4-[{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}(methyl)amino]cyclohexanecarbonitrile

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(2-pyridin-3-ylpiperidin-1-yl)propan-2-ol

1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}-4-phenylpiperidin-4-ol

2-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}amino)-3-methylbutan-1-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[4-(3-methoxyphenyl)piperazin-1-yl]propan-2-ol

or a pharmaceutically acceptable salt thereof.

13. (Original) A compound of formula (Ic)



(Ic)

wherein:

R^3 represents halogen, C1 to 3 alkyl or C1 to 3 alkoxy;

R^{10} represents H;

Ar represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S;

m represents an integer 1 or 2;

when m represents 1, R^1 represents OR^2;

when m represents 2, one R^1 represents chloro, NO_2 or OMe and the other R^1 represents OR^2;

R^2 represents C2 to 4 alkyl substituted by a group NR^6R^7;

R^6 represents H, C1 to 4 alkyl or $CH_2CH_2OCH_3$;

R^7 represents H, C1 to 6 alkyl, C3 to 6 cycloalkyl, Ar^3, a 5 or 6 membered saturated or partially unsaturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally substituted by Me, Et or CO_2Et; said C1 to 6 alkyl being optionally substituted by one or more groups selected independently from OH, CN, $CONMe_2$, CONHMe, C1 to 4 alkoxy, halogen, NMe_2, Ar^4, and a 5 or 6 membered saturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally also incorporating a carbonyl group; said C3 to 6 cycloalkyl being optionally substituted by OH or CN;

or the group $-NR^6R^7$ together represents a 5 or 6 membered saturated azacyclic ring optionally incorporating 1 additional heteroatom selected from O and NR^9; and optionally substituted by one or more substituents selected independently from OH, NMe_2, $CONH_2$, CH_2OH, CH_2CH_2OH, phenyl, pyridyl, piperidinyl or methoxyphenyl;

R^9 represents CH_2CH_2OH, $COCH_3$, Me, CO_2Et, CH_2CH_2OMe or a six membered aromatic or azaaromatic ring optionally further substituted by one or more substituents selected independently from Cl, CN, OMe and CF_3;

Ar^3 represents thiazolyl, triazolyl or tetrazolyl;

Ar^4 represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl, heteroaromatic or indole ring being optionally further substituted by one or two groups independently selected from halogen and OMe;
or a pharmaceutically acceptable salt thereof,
with the provisos that:

i) when R^6 represents H or C1 to 4 alkyl, R^3 does not represent unsubstituted C1 to 4 alkyl; and

ii) that the group $-NR^6R^7$ does not represent unsubstituted morpholine, thiomorpholine, 4-methylpiperazine or 4-phenylpiperazine.

14. (Original) A compound according to Claim 13 that is:
6-bromo-2-[4-(2-{4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}ethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine
6-bromo-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine
6-bromo-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-3H-imidazo[4,5-b]pyridine
6-bromo-2-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-3H-imidazo[4,5-b]pyridine
N-{2-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl}-*N*-(tetrahydrofuran-2-ylmethyl)amine
6-bromo-2-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3H-imidazo[4,5-b]pyridine
2-[{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}(methyl)amino]ethanol
3-[{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}(methyl)amino]propanenitrile

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}pyrrolidin-3-ol

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N,N-dimethylpyrrolidin-3-amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N,1-dimethylpyrrolidin-3-amine

N~2~-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N~1~,N~1~,N~2~-trimethylglycinamide

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-ethyl-N',N'-dimethylethane-1,2-diamine

N-benzyl-N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-methylamine

2-{4-[2-(4-acetylpiperazin-1-yl)ethoxy]phenyl}-6-bromo-3H-imidazo[4,5-b]pyridine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N,N-bis(2-methoxyethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-methyl-N-(2-phenylethyl)amine

6-bromo-2-{4-[2-(4-pyridin-2-ylpiperazin-1-yl)ethoxy]phenyl}-3H-imidazo[4,5-b]pyridine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-[3-(1H-imidazol-1-yl)propyl]amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(4-methoxybenzyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(3-methoxybenzyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(4-chlorobenzyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(3-chlorobenzyl)amine

ethyl 4-({2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amino)piperidine-1-carboxylate

6-bromo-2-(4-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethoxy}phenyl)-3H-imidazo[4,5-b]pyridine

1-({2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amino)propan-2-ol

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(2-methoxyethyl)amine

2-({2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amino)propan-1-ol

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(2-furylmethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(tetrahydrofuran-2-ylmethyl)amine

N-benzyl-N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(pyridin-3-ylmethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(pyridin-4-ylmethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(thien-2-ylmethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(1-phenylethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-1-ethylpiperidin-3-amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(2-morpholin-4-ylethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(2-methoxybenzyl)amine

1-[3-({2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amino)propyl]pyrrolidin-2-one

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-[2-(4-chlorophenyl)ethyl]amine

4-[{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}(methyl)amino]cyclohexanecarbonitrile

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidin-3-ol

6-bromo-2-{4-[2-(2-pyridin-3-ylpiperidin-1-yl)ethoxy]phenyl}-3H-imidazo[4,5-b]pyridine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-cyclopentylamine

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-4-phenylpiperidin-4-ol

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-[2-(1H-imidazol-4-yl)ethyl]amine

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidine-3-carboxamide

6-bromo-2-{4-[2-(4-pyrazin-2-ylpiperazin-1-yl)ethoxy]phenyl}-3H-imidazo[4,5-b]pyridine

(1*S*,2*S*)-2-({2-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl}amino)cyclohexanol

6-bromo-2-(4-{2-[4-(3-methoxyphenyl)piperazin-1-yl]ethoxy}phenyl)-3H-imidazo[4,5-b]pyridine

(1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidin-4-yl)methanol

4-({2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amino)cyclohexanol

(1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidin-2-yl)methanol

1'-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-1,4'-bipiperidine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-1,3-thiazol-2-amine

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidine-4-carboxamide

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-1H-1,2,4-triazol-3-amine

2-(4-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperazin-1-yl)benzonitrile

6-(4-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperazin-1-yl)nicotinonitrile

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}prolinamide

6-bromo-2-(4-{2-[4-(2-methoxyphenyl)piperidin-1-yl]ethoxy}phenyl)-3H-imidazo[4,5-b]pyridine

2-(4-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperazin-1-yl)ethanol

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidin-4-ol

6-bromo-2-(4-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethoxy}phenyl)-3H-imidazo[4,5-b]pyridine

(2*S*)-2-({2-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl}amino)-3-methylbutan-1-ol

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-4,5-dihydro-1,3-thiazol-2-amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-[2-(1H-indol-3-yl)ethyl]amine

(2*S*)-2-({2-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl}amino)-2-phenylethanol

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-1H-tetrazol-5-amine

(1*S*,2*R*)-2-({2-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl}amino)cyclohexanol

6-chloro-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3H-imidazo[4,5-b]pyridine

6-bromo-2-[4-(2-morpholin-4-ylethoxy)-3-nitrophenyl]-3H-imidazo[4,5-b]pyridine

or a pharmaceutically acceptable salt thereof.

15. (Original) A compound of formula (Id)



(Id)

wherein:

R^3 represents halogen, CN, C1 to 3 alkyl or C1 to 3 alkoxy;

Ar represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S;

R^1 represents H, halogen, CN, C1 to 6 alkyl, NO_2, SO_2Me, C1 to 6 alkynyl, CH_2OH, OR^2, $(CH_2)_nNR^4R^5$ or phenyl optionally substituted by NH_2;

m represents an integer 1 or 2; and when m represents 2, each R^1 may be selected independently;

n represents an integer 0 or 1;

R^2 represents H or C1 to 4 alkyl; said C1 to 4 alkyl being optionally further substituted by a group selected from Ar^1, $CONH_2$, CO_2Et, OH, NR^6R^7, halogen and epoxy; and when substituted by NR^6R^7 or halogen, said alkyl is optionally further substituted by OH;

R^4 represents H, C1 to 4 alkyl or CH_2Ar^2;

R^5 represents H, C1 to 6 alkyl, C2 to 6 alkanoyl, SO_2-Ar^5 or CH_2Ar^2; said alkyl group being optionally further substituted by a 5 to 7 membered saturated azacyclic ring optionally incorporating one additional heteroatom selected from O, S and NR^8;

or the group $-NR^4R^5$ together represents a 5 to 7 membered saturated azacyclic ring optionally incorporating one additional heteroatom selected from O, S and NR^8;

R^6 represents H, C1 to 4 alkyl or $CH_2CH_2OCH_3$;

R^7 represents H, C1 to 6 alkyl, C3 to 6 cycloalkyl, Ar^3, a 5 or 6 membered saturated or partially unsaturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally substituted by Me, Et or CO_2Et; said C1 to 6 alkyl being optionally substituted by one or more groups selected independently from OH, CN, $CONMe_2$, CONHMe, C1 to 4 alkoxy, halogen, NMe_2, Ar^4, and a 5 or 6 membered saturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally also incorporating a carbonyl group; said C3 to 6 cycloalkyl being optionally substituted by OH or CN;

or the group $-NR^6R^7$ together represents a 5 to 7 membered saturated azacyclic ring optionally incorporating 1 additional heteroatom selected from O and NR^9; and optionally substituted by one or more substituents selected independently from OH, NMe_2, $CONH_2$, CH_2OH, CH_2CH_2OH, phenyl, pyridyl, piperidinyl or methoxyphenyl;

R^8 represents H, C1 to 6 alkyl or CH_2Ph;

R^9 represents CH_2CH_2OH, $COCH_3$, Me, CO_2Et, CH_2CH_2OMe or a six membered aromatic or azaaromatic ring optionally further substituted by one or more substituents selected independently from Cl, CN, OMe and CF_3;

R^{10} represents halogen, CN, C1 to 4 alkyl, C1 to 4 alkoxy, $NR^{14}R^{15}$ or a group –X–Y–Z;

R^{14} and R^{15} independently represent H or C1 to 4 alkyl; said alkyl being optionally further substituted by OH;

X represents O, S, a bond or NR^{16} wherein R^{16} represents H or C1 to 4 alkyl; said alkyl being optionally further substituted by OH;

Y represents C1 to 4 alkyl or a bond;

Z represents:

i) phenyl, naphthyl or a 5- or 6-membered heteroaromatic ring system containing one to three heteroatoms independently selected from O, N and S; or

ii) a five- or six-membered saturated heterocyclic ring containing one or two heteroatoms independently selected from O, N and S; said ring optionally being benzo fused; or

iii) C3 to 6 cycloalkyl;

said ring Z being optionally substituted by one or more substituents independently selected from halogen, OH, C1 to 4 alkyl, C1 to 4 alkoxy, hydroxymethyl, methylsulphonyl and $NR^{17}R^{18}$;

R^{17} and R^{18} independently represent H, C1 to 4 alkyl, formyl or C2 to alkanoyl; or the group $NR^{17}R^{18}$ together represents a saturated 5 to 7 membered azacyclic ring optionally containing one further heteroatom selected from O, N and S;

Ar^1 represents phenyl, thiazolyl or thiadiazolyl, optionally further substituted by halogen;

Ar^2 represents phenyl, a 5- or 6-membered heteroaromatic ring or a benzimidazole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl or heteroaromatic or benzimidazole ring being optionally further substituted by one or two groups independently selected from halogen, C1 to 4 alkyl, CN, CH_2OH, C1 to 4 alkoxy, CO_2Me, CH_2OAc and pyridyl;

Ar^3 represents thiazolyl, triazolyl or tetrazolyl;

Ar^4 represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl, heteroaromatic or indole ring being optionally further substituted by one or two groups independently selected from halogen and OMe;

Ar^5 represents phenyl, a 5- or 6-membered heteroaromatic ring or a quinoline ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl or heteroaromatic or quinoline ring being optionally further substituted by halogen, C1 to 4 alkyl, CN, C1 to 4 alkoxy, and OCH_2CH_2CN;

with the proviso that when R^{10} represents halogen, C1 to 4 alkyl, C1 to 4 alkoxy or NH_2; and Ar represents phenyl; then said phenyl is not substituted at the 4-position by C1 to 2 alkoxy, OH, halogen or C1 to 4 alkyl.

16. (Original) A compound according to Claim 15 that is:

6,7-dichloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine

6-chloro-*N*-(2-methoxyphenyl)-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

2-[(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)amino]phenol

6-chloro-*N*-[1-(methylsulfonyl)-3-pyrrolidinyl]-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-*N*-cyclopentyl-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

N-benzyl-6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-7-(1*H*-pyrrol-1-yl)-1*H*-imidazo[4,5-*b*]pyridine

1-(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)-3-pyrrolidinamine

1-(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)-3-pyrrolidinylformamide

6-chloro-*N*-(2-ethylphenyl)-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-7-(2,3-dihydro-1*H*-indol-1-yl)-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridine

6-chloro-7-(4-morpholinyl)-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridine

6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-*N*-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-7-amine

[3-({6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridin-7-yl}amino)phenyl]methanol

6-chloro-*N*-(2-fluorophenyl)-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-*N*-phenyl-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-*N*-(3-ethylphenyl)-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

2-[benzyl(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)amino]ethanol

2-[(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)amino]ethanol

N-benzyl-6-chloro-*N*-methyl-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-*N*-methyl-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

7-(benzylthio)-6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridine

6-chloro-*N*-[4-(methylsulfonyl)phenyl]-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-*N*-[4-(4-morpholinyl)phenyl]-1*H*-imidazo[4,5-*b*]pyridin-7-amine

N'-(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)-*N*,*N*-*d*iethyl-1,4-benzenediamine

N-{4-[(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)amino]phenyl}acetamide

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-7-phenoxy-1*H*-imidazo[4,5-*b*]pyridine

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-7-[2-(1-pyrrolidinyl)ethoxy]-1*H*-imidazo[4,5-*b*]pyridine

6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-*N*-(2-morpholin-4-ylethyl)-3H-imidazo[4,5-b]pyridin-7-amine

6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-7-pyrrolidin-1-yl-3H-imidazo[4,5-b]pyridine

6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-*N*-(1-phenylethyl)-3H-imidazo[4,5-b]pyridin-7-amine

6-chloro-7-(4-methylphenyl)-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3H-imidazo[4,5-b]pyridine

6-chloro-7-(3-methoxyphenyl)-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3H-imidazo[4,5-b]pyridine

N-(3-{6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3H-imidazo[4,5-b]pyridin-7-yl}phenyl)acetamide

6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-7-thien-3-yl-3H-imidazo[4,5-b]pyridine

2-[4-(2-morpholin-4-ylethoxy)phenyl]-3H-imidazo[4,5-b]pyridine-6,7-dicarbonitrile

7-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine-6-carbonitrile

7-anilino-2-(4-{2-[(2-methoxyethyl)(methyl)amino]ethoxy}phenyl)-3*H*-imidazo[4,5-*b*]pyridine-6-carbonitrile

6,7-dichloro-2-{4-[2-(4-morpholinyl)ethoxy]-3-nitrophenyl}-1*H*-imidazo[4,5-*b*]pyridine

5-(6,7-dichloro-1*H*-imidazo[4,5-*b*]pyridin-2-yl)-2-[2-(4-morpholinyl)ethoxy]aniline

2-amino-5-(6-chloro-7-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenol

5-(6-chloro-7-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-2-{[(2*R*)-pyrrolidin-2-ylmethyl]amino}phenol

[5-(6-chloro-7-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-2-(2-morpholin-4-ylethoxy)phenyl][(2*R*)-pyrrolidin-2-ylmethyl]amine

4-(6-chloro-7-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-N^1-(2-morpholin-4-ylethyl)benzene-1,2-diamine

[5-(6-chloro-7-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-2-(4-methylpiperazin-1-yl)phenyl]amine

6,7-dichloro-2-[4-(4-morpholinyl)phenyl]-1H-imidazo[4,5-b]pyridine

[5-(6,7-dichloro-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-2-morpholin-4-ylphenyl]amine

2-(4-aminophenyl)-6-chloro-*N*-phenyl-3*H*-imidazo[4,5-*b*]pyridin-7-amine

N-[4-(6,7-dichloro-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(2-morpholin-4-ylethyl)amine

6-bromo-7-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3H-imidazo[4,5-b]pyridine

6-bromo-7-methyl-2-(4-nitrophenyl)-1*H*-imidazo[4,5-*b*]pyridine

4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)aniline

N-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-3-cyanobenzenesulfonamide

N-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-4-cyanobenzenesulfonamide

N-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]quinoline-8-sulfonamide

N-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-4-methoxybenzenesulfonamide

N-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-4-(2-cyanoethoxy)benzenesulfonamide

N-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-1-methyl-1*H*-imidazole-4-sulfonamide

N-[4-(6,7-dichloro-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-4-methoxybenzenesulfonamide

6-chloro-2-{4-[(2-morpholin-4-ylethyl)amino]phenyl}-*N*-phenyl-3*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-7-methoxy-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3H-imidazo[4,5-b]pyridine

6-chloro-2-{4-[di(3-cyanobenzyl)amino]phenyl}-7-methoxy-1-yl-3H-imidazo[4,5-b]pyridine

3-({[4-(6-chloro-7-methoxy-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]amino}methyl)benzonitrile)

N-[4-(6-chloro-7-methoxy-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-4-cyanobenzenesulfonamide

6-chloro-7-methoxy-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine

or a pharmaceutically acceptable salts thereof.

17. (Cancelled) .

18. (Currently amended) A process for the preparation of a compound of formula (Ia)~~, (Ib), (Ic) or (Id)~~ according to ~~any one of Claims 9 to 16~~ Claim 9 which comprises:

a) reaction of a compound of the general formula (II):



(II)

in which R^3 and R^{10} are as defined in Claim 9~~formula (Ia), (Ib), (Ic) or (Id)~~,

with a compound of formula (III):



(III)

in which m, R^1 and Ar are as defined in Claim 9 ~~formula (Ia), (Ib), (Ic) or (Id)~~, in the presence of an oxidizing agent; or

b) reaction of a compound of the general formula (II):



(II)

in which R^3 and R^{10} are as defined in Claim 9 ~~formula (Ia), (Ib), (Ic) or (Id)~~,

with a compound of formula (IV):



(IV)

in which m, R^1 and Ar are as defined in claim 9~~formula (Ia), (Ib), (Ic) or (Id)~~, in the presence of $POCl_3$; or

~~c) reaction of a compound of formula (V):~~



(V)

~~in which R^3, R^{10} and Ar are as defined in formula (Ib), (Ic) or (Id);~~

~~with a compound of formula (VI):~~

~~R^2-LG (VI)~~

~~in which R^2 is as defined in formula (Ib), (Ic) or (Id) and LG represents a leaving group; or~~

d) reaction of a compound of the general formula (VII):



(VII)

in which n, R^3, R^{10} and Ar are as defined in Claim 9 ~~formula (Ia) or (Id)~~;

with a compound of formula (VIII):

Ar^2-CHO (VIII)

in which Ar^2 is as defined in Claim 9~~formula (Ia) or (Id), or~~

~~e) reaction of a compound of the general formula (IX):~~



(IX)

~~in which R^3, R^{10} and Ar are as defined in formula (Ib) or (Id);~~

~~with a compound of formula (X):~~

~~HNR^6R^7 (X)~~

~~in which R^6 and R^7 are as defined in formula (Ib) or (Id);~~

and where desired or necessary converting the resultant compound of formula (Ia)~~, (Ib), (Ic) or (Id)~~ or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (Ia)~~, (Ib), (Ic) or (Id)~~ into another compound of formula (Ia)~~, (Ib), (Ic) or (Id)~~; and where desired converting the resultant compound of formula (Ia)~~, (Ib), (Ic) or (Id)~~ into an optical isomer thereof.

19. (Currently amended) A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (Ia)~~, (Ib), (Ic) or (Id)~~, according to ~~any one of Claims 9 to 16~~ Claim 9, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

20. (New) A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (Ib), according to Claim 11, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

21. (New) A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (Ic), according to Claim 13, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

22. (New) A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (Id), according to Claim 15, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

23. (New) A process for the preparation of a compound of formula (Ib) according to Claim 11 which comprises:

a) reaction of a compound of the general formula (II):



(II)

in which R^3 and R^{10} are as defined in Claim 11,

with a compound of formula (III):



(III)

in which m, R^1 and Ar are as defined in Claim 11, in the presence of an oxidizing agent; or

b) reaction of a compound of the general formula (II):



(II)

in which R^3 and R^{10} are as defined in Claim 11,

with a compound of formula (IV):



(IV)

in which m, R^1 and Ar are as defined in Claim 11, in the presence of $POCl_3$; or

c) reaction of a compound of formula (V):



(V)

in which R^3, R^{10} and Ar are as defined in Claim 11;

with a compound of formula (VI):

$$R^2\text{-LG} \qquad \text{(VI)}$$

in which R^2 is as defined in Claim 11 and LG represents a leaving group; or

e) reaction of a compound of the general formula (IX):



(IX)

in which R^3, R^{10} and Ar are as defined in Claim 11;

with a compound of formula (X):

$$HNR^6R^7 \qquad (X)$$

in which R^6 and R^7 are as defined in Claim 11;

and where desired or necessary converting the resultant compound of formula (Ib) or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (Ib) into another compound of formula (Ib); and where desired converting the resultant compound of formula (Ib) into an optical isomer thereof.

24. (New) A process for the preparation of a compound of formula (Ic) according to Claim 13 which comprises:

a) reaction of a compound of the general formula (II):



(II)

in which R^3 and R^{10} are as defined in Claim 13,

with a compound of formula (III):



(III)

in which m, R^1 and Ar are as defined in Claim 13, in the presence of an oxidizing agent; or

b) reaction of a compound of the general formula (II):



(II)

in which R^3 and R^{10} are as defined in Claim 13,

with a compound of formula (IV):



(IV)

in which m, R^1 and Ar are as defined in Claim 13, in the presence of $POCl_3$; or

c) reaction of a compound of formula (V):



(V)

in which R^3, R^{10} and Ar are as defined in Claim 13;

with a compound of formula (VI):

$$R^2\text{-LG} \qquad \text{(VI)}$$

in which R^2 is as defined in Claim 13 and LG represents a leaving group;

and where desired or necessary converting the resultant compound of formula (Ic) or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (Ic) into another compound of formula (Ic); and where desired converting the resultant compound of formula (Ic) into an optical isomer thereof.

25. (New) A process for the preparation of a compound of formula (Id) according to Claim 15 which comprises:

a) reaction of a compound of the general formula (II):



(II)

in which R^3 and R^{10} are as defined in Claim 15,

with a compound of formula (III):



(III)

in which m, R^1 and Ar are as defined in Claim 15, in the presence of an oxidizing agent; or

b) reaction of a compound of the general formula (II):



(II)

in which R^3 and R^{10} are as defined in Claim 15,

with a compound of formula (IV):



(IV)

in which m, R^1 and Ar are as defined in Claim 15, in the presence of $POCl_3$; or

c) reaction of a compound of formula (V):



(V)

in which R^3, R^{10} and Ar are as defined in Claim 15;

with a compound of formula (VI):

$$R^2\text{-LG} \qquad \text{(VI)}$$

in which R^2 is as defined in Claim 15 and LG represents a leaving group; or

d) reaction of a compound of the general formula (VII):



(VII)

in which n, R^3, R^{10} and Ar are as defined in Claim 15;

with a compound of formula (VIII):

$$Ar^2\text{-CHO} \qquad \text{(VIII)}$$

in which Ar^2 is as defined in Claim 15, or

e) reaction of a compound of the general formula (IX):



(IX)

in which R^3, R^{10} and Ar are as defined in Claim 15;

with a compound of formula (X):

$$HNR^6R^7 \qquad \text{(X)}$$

in which R^6 and R^7 are as defined Claim 15;

and where desired or necessary converting the resultant compound of formula (Id) or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (Id) into another compound of formula (Id); and where desired converting the resultant compound of formula (Id) into an optical isomer thereof.